Engflag

Raz PLUS

Quick links to important sections

Raz PLUS

Raz PLUS_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Raz PLUS

Understanding Raz PLUS

Raz PLUS is a combination medication developed to assist in the management of symptoms associated with Alzheimer's disease. It integrates two distinct pharmacological agents, galantamine and memantine, into a single therapeutic approach. This combination is typically utilized when a patient’s condition has progressed to a stage where a multifaceted approach to neurotransmitter regulation is considered appropriate.

Mechanism of Action

The two components of Raz PLUS work through different pathways in the central nervous system to address cognitive functions:

  • Galantamine: This component belongs to a class of drugs known as cholinesterase inhibitors. It works by increasing the concentration of acetylcholine, a chemical messenger in the brain involved in memory, awareness, and judgment. It also enhances the sensitivity of receptors to this neurotransmitter.
  • Memantine: This component is classified as an NMDA (N-methyl-D-aspartate) receptor antagonist. It functions by regulating the activity of glutamate, a chemical messenger involved in information processing and storage. By modulating glutamate levels, it helps protect nerve cells against excessive stimulation that can lead to dysfunction.

Therapeutic Intent

The primary goal of Raz PLUS is to support cognitive stability. While it is not a cure for underlying neurodegenerative conditions, it is intended to help manage symptoms such as confusion, memory loss, and difficulties with daily tasks. By combining these two mechanisms, the medication aims to provide more comprehensive support for brain function than either component used individually.

What side effects are possible with Raz PLUS?

Possible Side Effects and Safety Information

Frequency-Classified Adverse Reactions

The adverse reactions associated with Raz PLUS are formally categorized by their frequency of occurrence as documented in official regulatory sources. Events commonly reported include headache, dizziness, diarrhea, abdominal pain, nausea, and vomiting. Dryness of the mouth and flatulence are also noted in the official safety documents.

Serious Adverse Reactions and System-Organ Class Effects

The medicine's safety profile includes documentation of serious cardiac arrhythmias (irregular heartbeat), which pose a risk, particularly for individuals over 60 years of age. Adverse effects are classified by the body system affected, primarily involving Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Population-Specific Safety Considerations and Restrictions

Official regulatory information includes specific cautions for certain patient populations:

  • Liver and Kidney Impairment: Caution is advised for patients with existing liver or kidney disease; use is not recommended in cases of moderate to severe liver impairment.
  • Pregnancy and Breastfeeding: Use during pregnancy is not recommended unless the official risk-benefit assessment dictates otherwise. Official data suggests that the components pass into breast milk, making use during breastfeeding likely unsafe.
  • Hypersensitivity: The medicine is formally contraindicated (should not be used) in patients with a known allergy to its active components (rabeprazole or domperidone) or any of the inactive ingredients.

Driving or operating machinery is cautioned due to the officially reported potential for dizziness or drowsiness.

Overdose and Emergency Response

Overdose of Raz PLUS, a fixed-dose combination of Domperidone and Rabeprazole, necessitates immediate medical attention as described in official government regulatory documents. Documented clinical manifestations of overdose are largely derived from the Domperidone component, which affects the Central Nervous System. These presentations include somnolence, disorientation, and the appearance of extrapyramidal reactions, which are abnormal, involuntary body movements. Official regulatory notes specify that these extrapyramidal symptoms are more likely to occur in children following exposure.

The most critical, life-threatening outcome documented is the potential for QT interval prolongation leading to severe ventricular arrhythmias. Due to this documented cardiac risk, official guidance mandates that an individual seek medical attention straight away by contacting emergency services or a Poison Control Center when overdose is suspected.

Official management procedures for overdose are strictly defined as symptomatic treatment and supportive measures, as regulatory information confirms that no specific antidote is known. The clinical management, therefore, includes essential procedures such as ECG monitoring and continuous clinical status observation in a hospital setting. Furthermore, supportive steps like gastric lavage and administration of activated charcoal may be considered if done promptly.

Therapeutic Uses of Raz PLUS

Therapeutic Uses of Raz PLUS

Raz PLUS is a combination medication primarily utilized for the management of symptoms associated with neurodegenerative conditions, specifically Alzheimer's disease. By combining two distinct pharmacological agents, the medication addresses different mechanisms within the central nervous system to assist in the stabilization of cognitive function.

Core Indications

The primary use of this medication is for the treatment of moderate to severe dementia. It is intended for individuals who have already been stabilized on specific doses of the individual components or for those where a combination approach is deemed appropriate to manage the progression of cognitive decline.

Mechanisms of Action

Raz PLUS works by balancing chemical messengers in the brain that are essential for memory, learning, and overall cognitive processing:

  • Cholinergic Support: One component helps increase the levels of acetylcholine, a neurotransmitter involved in nerve cell communication, by inhibiting the enzymes that break it down.
  • Glutamate Regulation: The second component regulates the activity of glutamate, a chemical messenger that, when overactive, can lead to nerve cell damage.

Observed Benefits

While Raz PLUS does not cure underlying neurodegenerative diseases, it is utilized to achieve several therapeutic goals aimed at maintaining quality of life:

  • Cognitive Maintenance: Users may experience a slower rate of decline in memory, orientation, and language abilities.
  • Functional Support: The medication may assist patients in maintaining the ability to perform activities of daily living, such as grooming or eating, for a longer period.
  • Behavioral Stabilization: By regulating brain chemistry, the combination may help in managing some of the behavioral symptoms often associated with advanced dementia, such as agitation or confusion.

Eligibility and Restrictions for Use

Who Can and Cannot Use Raz PLUS?

The eligibility profile for Raz PLUS, a fixed-dose combination product, is strictly defined by the regulatory documentation for its two components, Rabeprazole and Domperidone.

Populations Allowed and Not Recommended: The medicine is primarily approved for use in Adults (18 years and older) with no documented contraindications. It is not recommended for children younger than 12 years of age due to lack of established safety data. Older adults require special monitoring due to a documented increased risk of cardiac adverse events.

Absolute Contraindications (Must Not Use): Use is strictly contraindicated in patients with the following conditions:

  • Known hypersensitivity to Rabeprazole, Domperidone, or other substituted benzimidazoles.
  • Moderate or severe hepatic impairment (liver dysfunction).
  • Underlying cardiac conditions, including QTc prolongation, congestive heart failure, or significant electrolyte disturbances (e.g., hypokalemia).
  • Gastrointestinal conditions such as hemorrhage, mechanical obstruction, or perforation.
  • A prolactin-releasing pituitary tumour (prolactinoma).

Pregnancy and Conditional Use: Raz PLUS is officially contraindicated during pregnancy and not recommended while breastfeeding. A mandatory restriction requires that the possibility of a gastric or esophageal malignancy be excluded prior to commencing treatment.

What should I know about interactions with other medicines?

The official interaction profile for Raz PLUS is structured around the distinct properties of its two active components. Due to the Domperidone component, co-administration is formally contraindicated with certain medicinal products. This restriction applies to potent CYP3A4 inhibitors (such as specific macrolide antibiotics and azole antifungals) and drugs known to cause QTc prolongation. The co-administration of these substances is prohibited because it increases Domperidone plasma exposure and heightens the risk of serious cardiac events.

The Rabeprazole component, a proton pump inhibitor, causes pH-dependent absorption interference. This pharmacokinetic interaction requires that the product must not be combined with certain oral antiretroviral medicines like Rilpivirine, Atazanavir, and Nelfinavir, as Rabeprazole may substantially reduce their exposure, risking loss of efficacy. Conversely, Rabeprazole may increase the plasma concentration of agents like Digoxin. Separation of administration time is a documented constraint for certain co-administered oncology agents.

Furthermore, Rabeprazole's interaction profile includes effects on specific metabolic pathways, documented by regulatory agencies. Co-administration with Warfarin has been associated with reports of increased International Normalized Ratio (INR), which necessitates clinical monitoring. The combination is also contraindicated in patients with moderate to severe hepatic impairment due to prolonged elimination of the Domperidone component, increasing exposure and associated risk.

Mechanism of Action

The action of Raz PLUS is achieved through a coordinated strategy targeting two distinct physiological pathways: acid secretion and gastrointestinal motility.

️ Irreversible Inhibition of Gastric Acid Secretion

This mechanism focuses on Rabeprazole, which acts as a prodrug that is selectively activated within the acid-producing cells of the stomach. Once activated, it delivers an irreversible inhibitory action on the H^+/ K^+-ATPase (Proton Pump) enzyme . By fundamentally halting the final step of H^+ ion exchange, this domain results in a substantial and sustained elevation of gastric pH, thereby influencing the chemical concentration of the gastric lumen.

Peripheral Dopamine D2 Receptor Antagonism

This mechanism involves Domperidone, which selectively blocks peripheral Dopamine D2 receptors primarily located in the wall of the digestive tract, without engaging central pathways. This antagonism removes an inhibitory influence on the enteric nervous system, leading to an enhancement of acetylcholine-driven muscle contraction. This domain’s physiological consequence is accelerated gastric emptying and increased tone of the Lower Esophageal Sphincter (LES), resulting in enhanced mechanical transit.

Mechanistic Synergy via Dual Pathway Correction

The drug operates under a principle of mechanistic synergy, combining the chemical-modulating domain (acid reduction) with the mechanical-modulating domain (motility enhancement). This combined action engages two distinct pathways simultaneously, producing a comprehensive physiological response in the upper digestive system.

Dosage and Administration Information

How to Use Raz PLUS

The administration of Raz PLUS, a fixed-dose combination containing Rabeprazole (20 mg) and Domperidone (30 mg SR), is based on established protocols. These protocols detail the required route, dosing schedule, and specific handling to ensure the integrity of the specialized formulation.

Administration Scope

Instruction Category Standard Protocol
Route of administration Oral use only.
Dosing schedule The standard adult regimen is one capsule daily.
Timing in relation to meals Must be taken before meals, typically specified as before breakfast, to optimize the action of the acid-suppressing component.
Special procedural conditions The capsule must be swallowed whole with liquid and must not be crushed or chewed to preserve the integrity of both the enteric-coated Rabeprazole and the sustained-release Domperidone components.

Procedural Structure and Adjustments

The core protocol dictates a simple, once daily oral administration pattern. The necessity of taking the medication before food establishes a clear timing requirement for the user.

A key procedural constraint involves population-specific use: for patients with severe renal impairment (Creatinine clearance less than 30 mL/min), the dosing frequency of the Domperidone component is reduced to account for altered elimination.

Official step sequence:

  • Confirm the dosage unit is one capsule containing Rabeprazole 20 mg and Domperidone 30 mg SR.
  • Take the capsule once daily before the first meal, such as breakfast.
  • Swallow the capsule whole with water.

This protocol defines the standardized method for using this medication.

Recent Clinical Evidence

Research evidence / Overview of studies for Raz PLUS

Evidence for Use in Gastroesophageal Reflux Disease (GERD) and Acid Reflux

Research was studied for the combination’s role in managing GERD symptoms, including severe and nighttime acid reflux. Studies applied in research contexts involving fluctuating or unstable symptoms have included systematic reviews and meta-analyses, alongside large-scale Real-World Evidence (RWE) observational studies. This research examined patient-reported outcomes describing perceived discomfort, such as heartburn scores, and measurements related to the healing of the esophageal lining.

Studies recorded measurable changes in patient symptom scores and compared them to those on acid suppression alone. Studies monitored the combination for patients whose research profiles indicated persistent nighttime heartburn. Long-term effects are not fully established, and comparative evidence is lacking from large, international studies, as much of the evidence is derived from specific geographical regions and includes studies of observational or non-comparative design.

Evidence for Use in Laryngopharyngeal Reflux Disease (LPRD)

The use of this combination was evaluated in research contexts involving conditions characterized by fluctuating or episodic manifestations like LPRD. Research examined the combination's application against acid suppression monotherapy in Randomized Controlled Studies that were often open-label. These studies focused on measuring outcomes related to physical discomfort by tracking changes in the Reflux Symptom Index (RSI) and the Reflux Finding Score (RFS), which assesses observable findings by a physician.

Some trials documented measurable changes in patient-reported RSI scores during the first four weeks, which were then compared between the combination group and the monotherapy group. However, findings were mixed concerning the physician-assessed RFS (laryngeal findings). The evidence is limited because sample sizes were modest in comparative trials, and follow-up durations were often limited to just a few weeks.

What is Still Uncertain About Raz PLUS

Certainty remains low for long-term effectiveness and maintenance of reported outcomes, as follow-up durations were limited in key comparative trials. Data for certain groups remain insufficient, including those in special populations such as children. Furthermore, the evidence base for conditions involving periods of heightened symptoms (primary motility disorders) is largely consensus-driven, meaning comparative evidence is lacking from high-quality trials for this specific use. The findings describe group patterns, and research does not determine whether an individual will respond similarly, necessitating further research to address these limitations.

Key Studies & References

  1. Expert opinion on the prescription practice of a combination of rabeprazole and domperidone for managing nighttime heartburn in GERD among Indian patients

Frequently Asked Questions (FAQ)

Common questions about Raz PLUS (FAQ)

Q: How quickly should I expect Raz PLUS to start working?

A: The components of Raz PLUS begin acting upon absorption, working to block acid production and stimulate digestive movement. The speed at which an individual feels symptom relief can vary. This dual action targets both the chemical reduction of acid and the enhancement of movement within the upper digestive system.

Q: Is it normal to feel tired when first starting Raz PLUS?

A: Official safety documents list asthenia (lack of energy) and somnolence (drowsiness or sleepiness) as reported adverse effects. Dizziness is also listed as a common side effect. The product label advises that any concerns about severe or persistent side effects should be discussed with a healthcare professional.

Q: Are there any foods I should avoid while on Raz PLUS?

A: Regulatory documents state that Raz PLUS must be taken before meals, typically before breakfast, to ensure the medicine works optimally. The official prescribing information does not list specific foods that must be avoided, but it should be noted that the administration instructions require it to be swallowed with liquid.

Q: Does Raz PLUS interact with over-the-counter pain relievers?

A: The official interaction profile details important restrictions with certain prescription medicines, such as strong CYP3A4 inhibitors and drugs that can affect heart rhythm. Specific over-the-counter pain relievers are not individually listed, but patients are generally advised that all co-administered products should be discussed with a healthcare professional to identify potential interactions.

Q: Can older people safely use Raz PLUS?

A: Older adults may use this medicine but require special monitoring due to a documented increased risk of cardiac (heart-related) adverse events, especially for individuals over 60 years of age. Any decision to use the medication requires an assessment of the balance of benefits and risks by a prescribing healthcare professional.

Q: Does taking Raz PLUS require any specific lab tests?

-A: Regulatory information advises that a serious underlying condition, such as a gastric or esophageal malignancy, should be ruled out before starting the treatment regimen. Monitoring for increased INR (clotting time) is also advised if the medication is being used alongside a blood thinner like Warfarin.

Q: Are there long-term side effects associated with Raz PLUS?

A: Long-term daily use (typically longer than 1 year) of the PPI component (Rabeprazole) is associated with an increased risk of specific conditions. These include Vitamin B12 deficiency, bone fracture, and low levels of magnesium in the blood ( Hypomagnesemia).

Q: Can Raz PLUS be taken with coffee or other caffeinated drinks?

A: The regulatory information does not list specific beverages to avoid. The capsule must be swallowed whole with liquid before the first meal. The medicine's timing is critical for its optimal performance.

Q: Why is the timing of Raz PLUS important?

A: The timing is important because Raz PLUS is designed to be taken before meals, typically before breakfast. This protocol ensures that the acid-suppressing component is fully active and optimized to manage the acid secretion that occurs naturally when food is consumed.

Q: Can Raz PLUS affect my sleep?

A: Official safety data lists both insomnia (difficulty sleeping) and somnolence (drowsiness) as reported undesirable effects. These side effects have the potential to affect sleep patterns. Any concerns about changes in sleep should be discussed with a healthcare professional.

Q: Why is hydration important when taking Raz PLUS?

A: The capsule must be swallowed whole with liquid for proper administration. The drug’s safety profile also notes potential side effects like dry mouth, and the component Domperidone is associated with risks of electrolyte imbalances (such as low potassium).

Q: Can I take Raz PLUS with my daily multivitamin?

A: Official documents do not specifically list multivitamins as interacting agents. However, the acid-reducing component ( PPI) can affect the absorption of certain vitamins and minerals, such as Vitamin B12 and magnesium, by changing the stomach’s pH level.

Q: Is Raz PLUS a type of antibiotic?

A: No. Raz PLUS is classified as a fixed-dose combination of an anti-ulcer agent (Rabeprazole) and a gastroprokinetic (Domperidone). Its mechanism is to reduce stomach acid and improve the movement of the stomach and small intestine, not to fight bacterial infections.

Q: Are there different strengths of Raz PLUS available?

A: The product information for this fixed-dose combination specifies a capsule containing Rabeprazole 20 mg and Domperidone 30 mg SR (sustained-release). Other strengths of this combination may exist, depending on the manufacturer and regional regulatory approvals.

Q: Does Raz PLUS affect blood pressure?

A: The Domperidone component carries a risk of serious cardiac arrhythmias (irregular heartbeat) and is contraindicated in patients with underlying cardiac conditions. While blood pressure effects are not directly stated, patients with pre-existing heart issues or electrolyte disturbances require caution.

Q: Is Raz PLUS for short-term use or long-term management?

A: The indications for the PPI component include both short-term treatment (such as for healing an ulcer) and long-term maintenance of healed conditions. The appropriate duration of therapy is determined by the specific diagnosis being treated, as documented in regulatory guidelines.

Q: Is it safe to drive after taking Raz PLUS?

A: Official prescribing information advises caution regarding driving or operating heavy machinery. This warning is based on the potential for side effects such as dizziness or drowsiness.

Q: Can taking Raz PLUS upset my stomach?

A: Yes. According to regulatory sources, commonly reported gastrointestinal side effects include abdominal pain, nausea, vomiting, diarrhea, constipation, and flatulence.

Q: Can Raz PLUS be crushed or split?

A: No. Official administration instructions require the capsule be swallowed whole with water and specifically state that it should not be crushed, chewed, or split. This is to maintain the integrity of the specialized enteric-coated and sustained-release components.

Q: What if I experience unusual mood changes while on Raz PLUS?

A: Official safety data lists psychiatric disorders, including insomnia, nervousness, and agitation, as reported undesirable effects. Any unusual or severe mood or behavior changes are conditions that should be discussed with a healthcare professional.

Q: Does Raz PLUS have any effect on kidney function?

A: Caution is advised for patients with existing kidney disease. For those with severe renal impairment (poor kidney function), the regulatory documents advise that the dosing frequency of the Domperidone component should be reduced.

How should Raz PLUS be stored and disposed of?

How to Store and Dispose of Raz PLUS

Official regulatory documents define strict environmental and handling requirements for Raz PLUS capsules.

Storage Requirements

Condition Regulatory Rule
Temperature Store at a temperature not exceeding 30 C
Protection Keep protected from light and moisture; Do not freeze
Packaging Must be kept in the original container and kept tightly closed
Safety Must be stored out of the sight and reach of children

Disposal Instructions

Expired or unused Raz PLUS must be disposed of according to local pharmaceutical take-back programs or regulations. The medicine should not be flushed down the toilet or poured into wastewater. If local take-back is unavailable, the official guidance for non-hazardous medicines recommends removing the medicine from the original container and mixing it with an unappealing substance, such as coffee grounds or dirt, then sealing the mixture in a bag before disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Raz PLUS found in:

A-Z Index: